Companies › BioCryst Pharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Berotralstat Plasma kallikrein inhibitor | KLKB1 | Phase 3 | Hereditary Angioedema | Feb 2027 |
| BCX17725 | – | Phase 1 | Netherton Syndrome | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06539507 | BCX17725 | Phase 1 | Netherton Syndrome | Immunology | Dec 2026 |
| NCT05453968 | Berotralstat | Phase 3 | Hereditary Angioedema | Immunology | Feb 2027 |
Cash and short-term investments of $375m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kyowa Kirin KalVista Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics
Pharvaris Netherlands KalVista Pharmaceuticals Sagimet Biosciences Hangzhou Highlightll Pharmaceutical Prime Gene Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.